Saturday, 31 December 2016

Happy New Year; Welcome 2017 with "Pharma Innovation Yatra" at your institute

A very Happy New Year to the readers of the blog. As a part of the Pharma Innovation Yatra 2017, we would be reaching pharmacy institutes all over India. 

So 2017 would be the year of going live, setting new trends for the blog. We at Pharma Literati would continue with many of the current activities and would be launching exciting new stuff for the readers.

Get in touch with us via email to know more about the creative thinking workshop and the Pharma Innovation Yatra. 

Starting from 15th January 2017. 

Pharma academic research - Indian patent applications published in the month of December 2016

Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at

Application Number
2nd December 2016
A controlled release formulation and a method of preparation thereof
1) Mohanty, Sanat
IIT, Delhi
Biphenyl analogs and their derivatives as antifungal agents
1) Megha Rikhi
2) Shanu Hoda
3) Swati Kaushik
4) Seema Bhatnagar
5) V. Pooja
6) Anjali Soni
7) B. Jayaram
Amity University, Noida
9th December 2016

16th December 2016
A method for preparing novel compounds for use as Cathepsin D enzyme inhibitoruseful in treatment of breast cancer
1) Perumal Yogeeswari
2) Dharmarajan Sriram
3) Anantaraju Hasitha Shilpa
4) Medapi Brahmam
BITS Pilani
Non-settling nanovesicular formulation for delivery of Amphotericin B
1) Subheet Kumar Jain
2) Lakhveer Kaur
3) Mohit Mahajan
Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab
23rd December 2016
Preparation of novel deferasirox analogues for antimalarial activity
1) Bhushan Vasant Dabholkar
2) Ganesh Baban Mule
St. Xaviers College 5, Mahapalika Marg, Mumbai-400 001, Maharashtra
30th December 2016
Novel nano gel formulation comprising silver sulfadiazine nanoformulation with aloe vera gel for treating burns and/or skin infections
1) MD. Abul Barkat
2) Satya Prakash Singh
3) Farhan J Ahmad
4) Iqbal Ahmad
5) Harshita
6) Raisuddin Ali
7) Faheem Hyder Pottoo
8) Sarwar Beg
Department of Pharmaceutics, Faculty of Pharmacy, Integral University, Lucknow, Uttra Pradesh
Intranasal Efavirenz nanoparticles for CNS targeting in neuro-aids
1) Ms. Aarti V. Belgamwar
2) Dr. Shagufta A. Khan
3) Dr. Pramod G. Yeole
Institute of Pharmaceutical Education and Research, Wardha, Maharashtra.
Ricinoleic acid glycoside compounds as antimicrobial agents
1855/DEL/2015 A
1) Kunnatheri Pallathu Madhom Ravindaranathan Kartha
2) Kuppala Ramakrishna
3) Mugunthan Govindarajan
4) Kamlesh Kumar Bhutani
5) Hemraj Nandanwar
NIPER, Mohali
Chitosan-G-poly (acrylamide)/copper nanocomposite for controlled drug delivery
1) Dr. Pathania Deepak
2) Gupta Divya
Shoolini University of Biotechnology and Management Sciences, Solan, Himachal Pradesh.

Friday, 30 December 2016

Updated Events Calendar

The blue highlighted events are updated over the last post.

1st Pharma Innovation Yatra 2017
Throughout 2017
Across India
Pharma Literati and FlexiTutr.
Seminar on ‘Facility qualification for oral
Solid formulation unit’.
11th Jan. 2017
NIPER, Mohali
Small and Medium Pharmaceutical Industry Centre
2nd International Conference on Clinical Pharmacy - CPCON Catalyzing Changes in Healthcare Practice
20th - 21st  Jan. 2017
Manipal, Karnataka
Manipal College of Pharmaceutical Sciences.
XXI quality improvement program on, “Trends in Pharmaceutical Sciences”
30th Jan - 10th Feb. 2017
DIPSAR, New Delhi.
8th International Symposium on Current Trends in Healthcare "Advances in New Drug Discovery And Development"
2nd - 4th Feb. 2017
Ahmedabad, Gujarat
Ramanbhai Foundation.
INNOPHARM 2_International Conference on Bridging Innovations in Pharmaceutical, Medical and Bio Sciences
10th - 11th Feb. 2017
Bhopal, Madhya Pradesh
Paramita Health Care Society.
2nd International Exhibition & Conference On
Pharmaceutical Industry
11th - 13th Feb. 2017
Bengaluru, Karnataka
Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers , Government of India
XXII quality improvement program on, “Current Scenario in Pharmaceutical Sciences”
13th Feb - 17th Feb. 2017
DIPSAR, New Delhi.
XVI pharmaquiz and IX Young pharmacist innovative project award 2017
17th Feb. 2017
Dombivali, Maharashtra
Sarswati Vidya Bhavan’s College of Pharmacy.
PharmaNeo 2017_International Conference on "Drug delivery system of Phytoconstituents - Past, Present & Future"
17th - 18th Feb. 2017
Bareilly, Uttar Pradesh
Invertis Institute of Pharmacy.
One Day Workshop on
“Unmet needs in drug delivery technologies”
Feb. 25, 2017
IIT, Bombay
IIT Bombay, IDMA and OPPI
XXIII quality improvement program on, “Update on Trends in Pharmaceutical Sciences”
27th Feb – 10th Mar. 2017
DIPSAR, New Delhi.
SPER 6th Annual International Conference & Exhibition 2017
3rd - 4th Mar. 2017
Jaipur, Rajasthan
Society of pharmaceutical education & Research.
International Conference on Challenges in Drug Discovery and Delivery (ICCD3 - 2017)
2nd - 4th Mar. 2017
Pilani, Rajasthan.
BITS, Pilani.

Thursday, 29 December 2016

As R&D returns take a hit, some pharmas are ramping up spending

Dive Brief:
• Amid intense scrutiny on pharmaceutical innovation and drug value, the industry saw far fewer novel drugs approved by the Food and Drug Administration in 2016 than in years past.
• Only 22 new molecular entities (NME) were approved this year, down substantially from the two-decade high of 45 last year.
• Adding to that poor showing, a new report published earlier this month put the projected returns from pharma's late-stage drug pipeline at a measly 3.7%. Taken together with the falling NME approvals, the report raises questions about the efficiency and success of pharma R&D.

Dive Insight:
The report, compiled by the consulting and accounting firm Deloitte, paints a picture of an industry caught between rising R&D costs on one hand and falling average projected peak sales on the other.

According to Deloitte, the cost to usher a drug from discovery all the way through launch - an elusive and usually controversial figure - stabilized at a little over $1.5 billion this year. At the same time, forecast sales per asset have dropped steadily in recent years, leading to an erosion of the projected returns from late-stage pipelines. 

Pricing backlash, coupled with a broad array of treatment options in many primary care areas, puts pharma under even more pressure to deliver clinically meaningful innovations. With that context in mind, BioPharma Dive has been collecting data to compare R&D spending as a percentage of product sales at notable companies to their industry peers. 

Sale of land by 3 PSU pharma firms cleared

The Cabinet on Wednesday approved the sale of surplus land of ailing state-owned pharma companies Indian Drugs & Pharmaceuticals Limited (IDPL), Rajasthan Drugs & Pharmaceuticals Limited (RDPL), and Bengal Chemicals & Pharmaceuticals Limited (BCPL) to pay off their existing liabilities.

While IDPL and RDPL will be closed down after settling their current liabilities, the Union government will explore the option to undertake a strategic sale of BCPL and Hindustan Antibiotics Limited at a later stage, according to an official statement.

In this way, the national assets would be utilized in the best national interest. The sale (of land) would be through open competitive bidding to government agencies and the outstanding liabilities will be met from the sale proceeds.”

The public sector firms have also been asked to implement a Voluntary Retirement Scheme and Voluntary Separation Scheme for their employees.

The remaining part of their land assets will be managed in accordance with norms set by the Department of Investment & Public Assets Management.

Wednesday, 28 December 2016

PCI instructs colleges to implement new rules & syllabus for B. Pharm & M. Pharm

The Pharmacy Council of India (PCI) has instructed all the pharmacy colleges to implement the newly introduced syllabus for B. Pharm and M. Pharm courses and also submit compliance of implementation of the same and regulations to PCI by August 1, 2017.

The council has instructed the colleges running the pharmacy courses to strictly follow the statutory provisions contained in the rules for B. Pharm and M. Pharm courses for approval under section 12(1) and 12(2) of the Pharmacy Act, 1948.

The further extension of approval of pharmacy institutions under section 12(1) and of the universities under section 12(2) of the Pharmacy Act, 1948 shall depend on the implementation of the B Pharm and M Pharm courses of study and syllabus prescribed by the PCI.

The PCI has recently come up with the final notification on M Pharm and B Pharm syllabus with an aim to make the syllabus of the said courses more of industry oriented by introducing uniform syllabus for the courses across the country.

The B. Pharm course has been divided into the semester and M Pharm is credit based semester system. As per the credit based semester system, certain quantum of academic work viz. theory classes, practical classes, seminars, assignments, etc. are measured in terms of credits and the candidate earns credits. The amount of credit associated with a course is dependent upon the number of hours of instruction per week in that course. Similarly the credit associated with any of the other academic, co/extra-curricular activities is dependent upon the quantum of work expected to be put in for each of these activities per week/per activity.

To address the employment problem faced by the students, the council will also have a tie-up with the industry for the recruitment of the M Pharm students. Along with DCGI, the council is planning a meeting with the industry associations to make them aware of the benefits of new syllabus as well as to urge the companies to tie-up for the recruitment. It will also request the industry to provide stipends to the students so that they are not exploited.

First phase of Pharma City to become operational by 2018

The first phase of prestigious Pharma City project on the outskirts of Hyderabad is moving at a faster pace and is expected to be completed by end of 2018. As part of this, the state government of Telangana has already acquired 5640 acres of land out of required 15,000 acres and had already started building basic infrastructure facilities like roads, drainage and common effluent treatment plants.

We are planning to build a chain-type Pharma City, which is designed as a self contained facility with residential townships for people working there in addition to a pharmaceutical university and a research centre among other things,” informed K. Taraka Rama Rao, minister for industries and information technology.

Conscious about environmental concerns, the state government of Telangana is encouraging the Pharma City project to be developed as a zero-liquid discharge facility while adequate precautions will be taken to make it environmentally safe and pollution free. “Pharma City is our dream project and the work is fast progressing. We are committed to make it operational by 2018,” said the minister.

The most important aspect of the Pharma City is the bulk drug manufacturing hub, which is expected to expand over an area of 8500 acres of land within the zone. This apart, formulation units, research centres and Pharma University along with residential zones for the employees of the Pharma City are some of the unique features constituting the pharma zone.

The overall cost of the Pharma City is estimated to be Rs.  75,000 crores. This mega pharma project is expected to house national and multinational pharmaceutical companies and life science related companies which would provide employment to lakhs of people.

According to Telangana State Industrial Infrastructure Corporation (TSIIC), the master plan for the entire Pharma City is still under preparation and the government is expected to come out with the complete design in the coming few days. “To garner financial support and assistance, we have sought loans from HUDCO and Asian Infrastructure Development Bank (AIDB) banks. By 2018 we are planning to complete the first phase,” informed a senior officer from TSIIC.